Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3099259 | 0.83 | FOLH1 (0.43) | MMEFOLH1TGFBR1 | |
| SCHEMBL5969046 | 0.82 | TGFBR1 (0.47) | MMEFOLH1TGFBR1 | |
| SCHEMBL5969049 | 0.82 | TGFBR1 (0.47) | MMEFOLH1TGFBR1 | |
| SCHEMBL3090622 | 0.81 | TGFBR1 (0.46) | MMEFOLH1TGFBR1 | |
| SCHEMBL3089426 | 0.81 | MAPT (0.43) | MMEFOLH1TGFBR1 | |
| SCHEMBL3100485 | 0.79 | MAPT (0.51) | — | |
| SCHEMBL3098909 | 0.78 | TGFBR1 (0.44) | MMEFOLH1TGFBR1 | |
| SCHEMBL3094826 | 0.78 | MME (0.48) | MMEMMP1MMP2MMP3MMP9 | |
| SCHEMBL18451327 | 0.76 | FOLH1 (0.46) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL3094205 | 0.74 | TSHR (0.45) | MMETGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531572-B2 | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use | XENOPORT, INC. (US) | 2009-05-12 | — | — | US | claimed |
| US-20080051458-A1 | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use | XENOPORT, INC. | 2008-02-28 | — | — | US | claimed |
| WO-2008013860-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF ALPHA-AMINO ACIDS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2008-01-31 | — | — | WO | claimed |
| US-7799829-B2 | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use | XENOPORT, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090192225-A1 | Acyloxyalkyl Carbamate Prodrugs of Alpha-Amino Acids, Methods of Synthesis and Use | XENOPORT, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| US-7531572-B2 | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use | XENOPORT, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080051458-A1 | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use | XENOPORT, INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008013860-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF ALPHA-AMINO ACIDS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192225-A1 | Acyloxyalkyl Carbamate Prodrugs of Alpha-Amino Acids, Methods of Synthesis and Use | ASNS, ASPH, DNPEP | MME 752/4885MMP1 1764/4885MMP2 2313/4885 |
| US-20080051458-A1 | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use | ASNS, ASPH, DNPEP | MME 752/4885MMP1 1764/4885MMP2 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.